Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat

Drug Profile

Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat

Alternative Names: Elvitegravir/Truvada/GS 9350; EVG/FTC/TDF/cobicistat FDC Quad tablet; Quad; Stribild

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Deoxyribonucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 15 Sep 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval for HIV-infections (Treatment-experienced, In adolescents, In adults) in European Union
  • 13 Sep 2017 Preregistration for HIV-1 infections (Treatment-experienced, In adolescents, In adults) in United Kingdom (PO) before September 2017
  • 27 Feb 2017 Gilead Sciences has patent protection for elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat in USA and European Union (Gilead Sciences 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top